Guardant Health, Inc.

Equities

GH

US40131M1099

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
101.85 ^USD	+3.55%		-10.69%	-0.28%

02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

Transcript : Guardant Health, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03

Published on 01/13/2026 at 12:50 am GMT - Modified on 01/13/2026 at 03:05 am GMT

S&P Capital IQ

Presenter Speech
Casey Woodring (Analysts)

All right. Great. I think we can get started here. Hi, everybody. My name is Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Guardant Health, Inc.

02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
01-22	Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	CI
01-22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT
01-19	Guardant Health announces multi-year strategic collaboration agreement with Merck	RE
01-19	Guardant Health, Inc. Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform	CI
01-13	Guardant Health, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:45 PM
01-12	Guardant Health shares up 2.4% after preliminary Q4 revenue beats estimates	RE
01-12	Independence, Under Review
01-12	Guardant Health Sees 39% Rise in Q4 Preliminary Revenue	MT
01-11	Guardant Health Q4 total revenue of approx $280 million	RE
01-11	Guardant Health, Inc. Provides Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
01-08	Guardant Health, Inc.'S Shield Blood Test for Colorectal Cancer Screening Now Available for U.S. Military Members and Families	CI
12-18	Guardant Health Insider Sold Shares Worth $9,402,220, According to a Recent SEC Filing	MT
12-11	Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S	CI
12-11	Guardant Health Forms Collaboration With Trial Library to Increase US Access to Cancer Clinical Trials	MT
12-11	Guardant Health Insider Sold Shares Worth $10,505,474, According to a Recent SEC Filing	MT
12-11	Guardant Health Insider Sold Shares Worth $2,417,980, According to a Recent SEC Filing	MT
12-09	Guardant Health, Inc. and Policlinico Gemelli Launch In-House Liquid Biopsy Testing Service in Italy	CI
12-09	Guardant Health Insider Sold Shares Worth $3,241,621, According to a Recent SEC Filing	MT
12-09	Guardant Health Insider Sold Shares Worth $8,288,742, According to a Recent SEC Filing	MT
12-09	Guardant Health Insider Sold Shares Worth $3,066,817, According to a Recent SEC Filing	MT
12-05	Certain Common Stock of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
12-05	Certain Options of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI
12-05	Certain Restricted Stock Units of Guardant Health, Inc. are subject to a Lock-Up Agreement Ending on 5-DEC-2025.	CI